Status Epilepticus Refractory to Two Agents in a Patient With Renal Failure
A 61-year-old man with ESRD on hemodialysis presents in generalized convulsive status epilepticus. He received 10 mg IV lorazepam in the field and 4 mg more in the ED, then levetiracetam 60 mg/kg IV load (his weight is 90 kg). He continues to convulse intermittently and is now intubated. Creatinine 7.8, potassium 6.1, bicarbonate 14. BP 158/88, HR 102. He has not yet been dialyzed this week. The pharmacy notes that levetiracetam is renally cleared and his level may be high.
1. He is refractory to benzodiazepines and levetiracetam. What is your next agent, and how does ESRD change the choice?
Read the worked answer
Refractory status epilepticus after adequate benzodiazepines warrants a second-line agent: fosphenytoin, valproate, levetiracetam, or lacosamide are the standard options. Here, levetiracetam is already used and renally cleared (dose-adjust in ESRD; a 60 mg/kg load is high but acceptable acutely, with maintenance reduced). For the next agent in ESRD: valproate is hepatically metabolized and not renally cleared, but it can cause hyperammonemia and is avoided in liver disease; fosphenytoin is hepatically metabolized but has saturable kinetics and can cause hypotension; lacosamide is renally cleared (needs adjustment) and can prolong PR. Given his metabolic derangement (K 6.1, bicarb 14), fosphenytoin's hypotension risk and lacosamide's renal clearance are considerations. A reasonable choice is valproate (hepatic clearance) if liver function is acceptable, or fosphenytoin with careful BP monitoring. If seizures persist, move to a continuous infusion (midazolam, propofol, or pentobarbital) with EEG burst suppression.
2. He remains in electrographic status on continuous EEG. You start a midazolam infusion. What monitoring and dose adjustments are required given his renal failure?
Read the worked answer
Midazolam is hepatically metabolized to active metabolites (alpha-hydroxymidazolam) that accumulate in renal failure and can prolong sedation and seizure control unpredictably - this is a key ESRD consideration. Monitor with continuous EEG to titrate to burst suppression (or seizure suppression), and be prepared for prolonged emergence. Watch for hypotension (he is on no pressors now but midazolam causes vasodilation), and monitor for propylene glycol toxicity if using high-dose lorazepam or a propofol formulation (metabolic acidosis, elevated anion gap, osmolar gap - he already has bicarb 14). If midazolam fails or metabolites cause problems, pentobarbital (hepatic) is an alternative but causes more hypotension. Also arrange urgent hemodialysis - it will correct K 6.1, bicarb 14, and clear some drug metabolites, and dialysis itself can lower seizure threshold transiently, so coordinate with neurology.
3. What is the role of urgent dialysis in this admission, and what is the risk of dialyzing a patient in status epilepticus?
Read the worked answer
Urgent dialysis is indicated for his hyperkalemia (K 6.1), severe metabolic acidosis (bicarb 14), and uremia, and it will also clear renally excreted antiseizure drugs and active metabolites (e.g., of midazolam, levetiracetam). The risk: dialysis can cause rapid shifts in electrolytes, osmolality, and blood pressure, and can transiently lower seizure threshold or cause disequilibrium syndrome; hypotension during dialysis can worsen cerebral perfusion in a patient with ongoing status. Mitigate by: using a slower dialysis prescription, avoiding rapid osmolar shifts, maintaining BP with careful ultrafiltration, and continuing EEG monitoring through the session. Coordinate timing with neurology and the ICU - do not delay dialysis for hyperkalemia, but do not dialyze without seizure and hemodynamic monitoring.